Dogwood Therapeutics 株価情報 (NASDAQ: DWTX)

最新ニュース Dogwood Therapeutics (NASDAQ:DWTX) 株価情報

Dogwood Therapeutics

Dogwood Therapeutics Inc, formerly Virios Therapeutics Inc, is a development-stage biotechnology company. It is focused on advancing novel antiviral therapies to treat diseases associated with a virus-triggered abnormal immune response, such as fibromyalgia (FM) and long COVID (LC). Its product candidates include IMC-1 and IMC-2. IMC-1 is intended to synergistically suppress herpesvirus activation and replication with a more specific activity against the Epstein-Barr virus (herpesvirus HHV-4, IMC-2 is a combination of valacyclovir and celecoxib.

Dogwood Therapeutics, Inc. - Common Stock

Dogwood Therapeutics Inc

Keefe, Bruyette &amp; Woods analyst Jade Rahmani maintains Ready Capital (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RC#NYSE">RC</a>) with a Underperform and lowers the price target from $4 to $3.75.

News

Price Target

Analyst Ratings

Keefe, Bruyette & Woods Maintains Underperform on Ready Capital, Lowers Price Target to $3.75

WIIM

ACHC

Acadia Healthcare shares are trading higher after the company reported better-than-expected Q1 financial results.

RBC Capital analyst Brian Abrahams maintains Karyopharm Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KPTI#NASDAQ">KPTI</a>) with a Outperform and lowers the price target from $34 to $33.

KPTI

RBC Capital Maintains Outperform on Karyopharm Therapeutics, Lowers Price Target to $33

Maravai LifeSciences Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRVI#NASDAQ">MRVI</a>) reported mixed results for the <a href="https://www.benzinga.com/quote/MRVI/earnings">first quarter on Monday</a>.
The company posted quarterly losses of 8 cents per share which missed the analyst consensus estimate of losses of 7 cents per share. The company reported quarterly sales of $46.85 million which beat the analyst consensus estimate of $44.01 million.
&#8220;Our first quarter revenue exceeded our guidance range, and our base business, which excludes revenue from high-volume CleanCap&#xAE; for commercial vaccine programs, grew more than $4 million compared to the fourth quarter of 2024, reflecting solid execution and momentum across the business,&#8221; said Trey Martin, CEO, Maravai LifeSciences. &#8220;Our team remains committed to our return-to-growth strategy amid a dynamic and shifting macroeconomic environment. We believe our customer focus, our differentiated technologies and GMP services supporting clients from discovery through commercialization give us the best position to continue navigating the evolving landscape and drive long-term value for Maravai.&#8221;
Maravai LifeSciences said it sees FY2025 sales of $185.00 million to $205.00 million, versus market estimates of $192.75 million.
Maravai LifeSciences shares fell 3.5% to trade at $2.0450 on Tuesday.
These analysts made changes to their price targets on Maravai LifeSciences following earnings announcement.
<ul class="wp-block-list">
<li>Baird analyst Catherine Schulte maintained Maravai LifeSciences with a Neutral and lowered the price target from $3 to $2.</li>
<li>Craig-Hallum analyst Christian Schwab maintained the stock with a Buy and lowered the price target from $12 to $10.</li>
</ul>
Considering buying MRVI stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="632" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/13132556/image-147-1024x632.png" alt="" class="wp-image-913945" style="width:609px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/13132556/image-147-1024x632.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/13132556/image-147-300x185.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/13132556/image-147-768x474.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/13132556/image-147.png 1081w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read This Next: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/trading-ideas/long-ideas/25/05/45375319/jim-cramer-ok-harrow-recommends-buying-this-energy-stock">Jim Cramer Is &#8216;OK&#8217; With Harrow, Recommends Buying This Energy Stock</a> </li>
</ul>
Photo via Shutterstock

Earnings

Markets

Trading Ideas

MRVI

These Analysts Slash Their Forecasts On Maravai LifeSciences Following Q1 Results

Keefe, Bruyette &amp; Woods analyst Ryan Krueger maintains Voya Financial (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VOYA#NYSE">VOYA</a>) with a Outperform and raises the price target from $80 to $83.

VOYA

Keefe, Bruyette & Woods Maintains Outperform on Voya Financial, Raises Price Target to $83

FLOC

Flowco Holdings shares are trading lower after the company reported worse-than-expected Q1 sales results.

Keefe, Bruyette &amp; Woods analyst Ryan Krueger maintains Jackson Finl (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JXN#NYSE">JXN</a>) with a Market Perform and raises the price target from $90 to $100.

Keefe, Bruyette & Woods Maintains Market Perform on Jackson Finl, Raises Price Target to $100

As <a href="https://www.forbes.com/sites/javierhasse/2025/04/22/is-america-missing-out-on-the-global-cannabis-boom/">cannabis goes global</a>, some of the world's largest companies are starting to show their hand. One of them is Philip Morris International Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PM#NYSE">PM</a>), the world's biggest tobacco company by market cap and one of the most deliberate players in the <a href="https://www.benzinga.com/cannabis">cannabis space</a>.
While peers like Altria and British American Tobacco (BAT) have made splashier moves into recreational marijuana markets, PMI has taken a quieter, more clinical approach: targeting medical cannabis, forming R&amp;D alliances and testing products in tightly regulated markets like Canada.
While often overlooked, its cannabis strategy is beginning to take shape, and its latest partnerships suggest this is just the beginning.
<h3 class="wp-block-heading">A Decade In The Making: PMI's Measured Cannabis Timeline</h3>
PMI's interest in cannabis began almost a decade ago. In 2016, it made a strategic investment in Syqe Medical, an Israeli company known for its precision-dose cannabis inhaler. That investment eventually culminated in full acquisition in 2023, marking PMI's first major cannabis takeover.
Fast forward to 2024–2025, and PMI's footprint has expanded through its pharmaceutical and wellness subsidiary, Vectura Fertin Pharma:
<ul class="wp-block-list">
<li>In September 2024, Vectura launched its first cannabis product, the Luo CBD lozenge, distributed via a partnership with Aurora Cannabis Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACB#NASDAQ">ACB</a>) and its Canadian medical platform.</li>
<li>In January 2025, PMI and Avicanna Inc. (OTC:<a class="ticker" href="https://www.benzinga.com/stock/AVCNF#OTC">AVCNF</a>), a cannabinoid-focused biopharma company, announced a medical and scientific collaboration to further research and patient access through Avicanna's <a class="" href="https://www.mymedi.ca/">MyMedi.ca</a> platform.</li>
</ul>
"PMI has consistently shown interest in the medical side of cannabis," said Aaron Grey, managing director at Alliance Global Partners, in a Forbes <a href="https://www.forbes.com/sites/javierhasse/2025/01/19/worlds-largest-tobacco-company-continues-silent-entry-into-cannabis-is-philip-morris-a-medical-marijuana-supporter/">interview</a>. "This seems like a continuation of that strategy."
<h3 class="wp-block-heading">Medical First, Consumer Later?</h3>
PMI's strategy stands in stark contrast to Altria, which invested <a class="" href="https://www.businesswire.com/news/home/20181207005164/en/Altria-to-Make-Growth-Investment-in-Cronos-Group">$1.8 billion in Cronos Group</a>, and BAT, which has a CAD 125 million <a class="" href="https://stratcann.com/news/global-tobacco-giant-ups-investment-in-canadian-cannabis-producer-organigram/">partnership with Organigram</a>. Those moves have largely centered on consumer products or adult-use cannabis.
PMI, by contrast, is avoiding recreational markets for now and focusing on evidence-based, dose-controlled therapeutics that fit within healthcare systems. Its partner Avicanna is a good example: the company works with SickKids Hospital, the University Health Network and was formerly part of Johnson &amp; Johnson's JLABS incubator.
Also read: <a href="https://www.benzinga.com/general/health-care/25/02/43666635/zyn-changed-nicotine-forever-are-cannabis-pouches-the-next-big-thing">Zyn Changed Nicotine Forever &#8211; Are Cannabis Pouches The Next Big Thing?</a>
"This is a multi-decade strategy," Grey said. "Big Tobacco sees usage trends shifting among younger consumers, away from tobacco and alcohol and toward cannabis. PMI is playing the long game."
<h3 class="wp-block-heading">Why Canada?</h3>
PMI's recent activity is centered in Canada, where federal regulations allow for robust medical cannabis distribution and clinical validation.
Its 2024 partnership with Aurora introduced a novel, dissolvable CBD lozenge for patients, manufactured by Vectura's subsidiary Cogent and offered through Aurora's direct-to-patient network.
"The launch will enable us to make a meaningful impact to patients and to validate our product&#8217;s proposition through real-world patient data," said Michael Kunst, CEO of Vectura Fertin Pharma, in a statement.
Meanwhile, the Avicanna partnership helps PMI integrate into Canada's pharmacist-led medical system, aligning with its reputation-driven, regulatory-first approach.
<h3 class="wp-block-heading">Analysts Weigh In: A Cautious But Serious Entry</h3>
Some believe PMI's partnerships could lead to acquisitions, much like the Syqe Medical trajectory.
"This could follow a similar path," Grey said, "depending on how the collaboration performs."
Others urge patience.
"It's way too early to say," said Dan Ahrens, managing director at AdvisorShares. "We've seen limited activity so far and we believe companies like PMI are waiting for broader regulatory clarity, particularly in the U.S."
"The rate and pace of integration will be dictated by the regulatory landscape," Todd Harrison, founder of CB1 Capital, added on Forbes. "But this is yet another proof point of the eventual entry of traditional CPG."
<h3 class="wp-block-heading">The Bottom Line</h3>
Rather than pursuing high-visibility consumer trends, Philip Morris is investing in infrastructure, focusing on product validation and building a presence in the medical cannabis sector.
In doing so, it's laying the foundation for a more permanent role in the global cannabis market, which doesn't rely on flashy branding but on science, patient access, and regulatory credibility.
As the industry matures, PMI's strategy may prove more durable than louder, riskier entries. And if the U.S. eventually legalizes cannabis at the federal level, don't be surprised if Philip Morris is already in position, ready to scale what it has quietly built.
Now read:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/cannabis/25/05/45380854/cannabis-sales-are-up-but-jobs-are-down-why-insiders-call-it-a-strategic-reset-for-survival">Cannabis Sales Are Up, But Jobs Are Down: Why Insiders Call It A Strategic Reset For Survival</a></li>
</ul>
Photo: Shutterstock

Biotech

Cannabis

AVCNF

World's Largest Tobacco Company Is Investing In Medical Cannabis: Here's What To Know

PBF Energy shares are trading highera fter UBS upgraded the stock from Neutral to Buy and raised its price target from $20 to $26. Also, Mizuho raised its price target on from $22 to $23.

NuScale Power shares are trading higher followinga Q1 revenue beat.

Keefe, Bruyette &amp; Woods analyst Ryan Krueger maintains Genworth Financial (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GNW#NYSE">GNW</a>) with a Market Perform and raises the price target from $8 to $8.5.

Keefe, Bruyette & Woods Maintains Market Perform on Genworth Financial, Raises Price Target to $8.5

RBC Capital analyst Kenneth Lee maintains Victory Capital Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VCTR#NASDAQ">VCTR</a>) with a Outperform and raises the price target from $72 to $75.

VCTR

RBC Capital Maintains Outperform on Victory Capital Holdings, Raises Price Target to $75

Life360 shares are trading higher after the company reported better-than-expected Q1 financial results and several firms raised their respective price targets on the stock.

<figure class="wp-block-image size-large"><img decoding="async" src="https://thearorareport.com/wp-content/uploads/2025/05/2025-05-13_08h43_42.png" alt="" /></figure>
To gain an edge, this is what you need to know today.
<h4 class="wp-block-heading">Lower Probability Of Stagflation And Recession</h4>
Please <a href="https://thearorareport.com/stock-market-chart-analysis-cooler-consumer-price-index-cpi-spy-mc-05132025">click here</a> for an enlarged chart of SPDR S&amp;P 500 ETF Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>) which represents the benchmark stock market index S&amp;P 500 (SPX).
Note the following:
<ul class="wp-block-list">
<li>The chart shows the stock market did not break above the breakout line on yesterday's rally.</li>
<li>The chart shows volume yesterday was not heavy, indicating that there is not high conviction in the jump.</li>
<li>Stock market bulls are expecting the market to quickly reach zone 1 (resistance) shown on the chart.</li>
<li>Stock market bears are scratching their heads trying to figure out why President Trump gave China everything it wanted, leaving the U.S with almost nothing in exchange.&nbsp; Bulls respond by saying President Trump has managed to get China to agree to open up to American goods by removing non-monetary barriers.</li>
<li>In our analysis, prudent investors need to remember that China has been promising to open up ever since President Nixon.  China has always talked a good game about opening up, but in reality, it has always maintained restrictions.  </li>
<li>The chart shows the stock market remains below the breakout line after the Consumer Price Index (CPI) came cooler than expected.&nbsp; Here are the details: 
<ul class="wp-block-list">
<li>Headline CPI came at 0.2% vs. 0.3% consensus.</li>
<li>Core CPI came at 0.2% vs. 0.3% consensus.</li>
</ul>
</li>
<li>In our analysis the probabilities of stagflation and recession have decreased.  The reason is the great deal China secured on tariffs.  On the campaign trail, President Trump had promised 60% tariffs on Chinese goods.  Once fentanyl tariffs are removed tariffs on Chinese goods will be only 10%.  As a reference, tariffs on the U.S.'s best ally, the U.K., are also 10%.  The U.S. runs a trade surplus with the U.K. and a massive trade deficit with China.       
<ul class="wp-block-list">
<li>According to our analysis, the probability of stagflation is now 60%, down from 70% prior.</li>
<li>According to our analysis, the probability of a recession is now 35%, down from 40% prior.  </li>
</ul>
</li>
<li>Treasury Secretary Scott Bessent says the deal with the E.U. will be "a bit slower," but he is optimistic about trade deals with Asian countries.</li>
<li>Ignore the Dow Jones Industrial Average (DJIA) this morning – the drop in DJIA is due to UnitedHealth Group Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UNH#NYSE">UNH</a>) suspending guidance.</li>
</ul>
<h4 class="wp-block-heading">Magnificent Seven Money Flows</h4>
In the early trade, money flows are positive in Amazon.com, Inc. (AMZN), Alphabet Inc Class C (GOOG), Meta Platforms Inc (META), NVIDIA Corp (NVDA), and Tesla Inc (TSLA).
In the early trade, money flows are neutral in Apple Inc (AAPL).
In the early trade, money flows are negative in Microsoft Corp (MSFT).
In the early trade, money flows are positive in S&amp;P 500 ETF (SPY) and Invesco QQQ Trust Series 1 (QQQ).
<h4 class="wp-block-heading">Momo Crowd And Smart Money In Stocks</h4>
Investors can gain an edge by knowing money flows in SPY and QQQ.&nbsp; Investors can get a bigger edge by knowing when smart money is buying stocks, gold, and oil.&nbsp; The most popular ETF for gold is SPDR Gold Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GLD#NYSE">GLD</a>).&nbsp; The most popular ETF for silver is iShares Silver Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SLV#NYSE">SLV</a>).&nbsp; The most popular ETF for oil is United States Oil ETF (ASCA:USO).
<h4 class="wp-block-heading">Bitcoin</h4>
Bitcoin is seeing buying.
The crypto exchange company Coinbase Global Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COIN#NASDAQ">COIN</a>) is being added to the S&amp;P 500.&nbsp; COIN will replace Discover Financial Services (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DFS#NYSE">DFS</a>) on May 19.&nbsp; COIN is up about 11% as of this writing in the premarket.
<h4 class="wp-block-heading">Arora Protection Band And What To Do Now</h4>
It is important for investors to look ahead and not in the rearview mirror.  our proprietary Protection Band puts all of the data, all of the indicators, all of the news, all of the crosscurrents, all of the models, and all of the analysis in an analytical framework that is easily actionable by investors.
Consider continuing to hold good, very long term, existing positions. Based on individual risk preference, consider a protection band consisting of cash or Treasury bills or short-term tactical trades as well as short to medium term hedges and short term hedges. This is a good way to protect yourself and participate in the upside at the same time.
You can determine your protection bands by adding cash to hedges.&nbsp; The high band of the protection is appropriate for those who are older or conservative. The low band of the protection is appropriate for those who are younger or aggressive.&nbsp; If you do not hedge, the total cash level should be more than stated above but significantly less than cash plus hedges.
A protection band of 0% would be very bullish and would indicate full investment with 0% in cash.&nbsp; A protection band of 100% would be very bearish and would indicate a need for aggressive protection with cash and hedges or aggressive short selling.
It is worth reminding that you cannot take advantage of new upcoming opportunities if you are not holding enough cash.&nbsp; When adjusting hedge levels, consider adjusting partial stop quantities for stock positions (non ETF); consider using wider stops on remaining quantities and also allowing more room for high beta stocks.&nbsp; High beta stocks are the ones that move more than the market.
<h4 class="wp-block-heading">Traditional 60/40 Portfolio</h4>
Probability based risk reward adjusted for inflation does not favor long duration strategic bond allocation at this time.
Those who want to stick to traditional 60% allocation to stocks and 40% to bonds may consider focusing on only high quality bonds and bonds of five year duration or less.&nbsp; Those willing to bring sophistication to their investing may consider using bond ETFs as tactical positions and not strategic positions at this time.
The Arora Report is known for its accurate calls. The Arora Report correctly called the big artificial intelligence rally before anyone else, the new bull market of 2023, the bear market of 2022, new stock market highs right after the virus low in 2020, the virus drop in 2020, the DJIA rally to 30,000 when it was trading at 16,000, the start of a mega bull market in 2009, and the financial crash of 2008. Please click here to sign up for a free forever <a href="https://thearorareport.com/generate-wealth-newsletter-benzinga">Generate Wealth Newsletter</a>.

Equities

Government

Long Ideas

Market Summary

Broad U.S. Equity ETFs

Opinion

COIN

Lower Probability Of Stagflation And Recession, Cooler CPI

HALO

Halozyme Therapeutics shares are trading lower after Leerink Partners downgraded the stock from Market Perform to Underperform and announced a price target of $47.

MNDY

Monday.com shares are trading higher after the company on Monday raised its guidance.

Keefe, Bruyette &amp; Woods analyst Ryan Krueger maintains Brighthouse Finl (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BHF#NASDAQ">BHF</a>) with a Market Perform and raises the price target from $56 to $59.

Brighthouse Financial, Inc. - Common Stock

Keefe, Bruyette & Woods Maintains Market Perform on Brighthouse Finl, Raises Price Target to $59

Telefonica Brasil shares are trading higher following Q1 financial results.

AMC Entertainment Holdings Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AMC#NYSE">AMC</a>) shares climbed 1% to $2.75 Tuesday afternoon following the company's <a href="https://www.benzinga.com/pressreleases/25/05/b45363218/amc-theatres-to-make-moviegoing-more-affordable-with-a-major-pricing-initiative-beginning-july-9-a">announcement</a> of a new nationwide ticket discount initiative.
What To Know: Starting July 9, AMC Theatres will offer "50% Off Wednesdays" to all AMC Stubs members, providing half-price adult evening tickets every Wednesday at all U.S. locations. Membership to AMC Stubs Insider is free.
Read Also: <a href="https://www.benzinga.com/general/entertainment/25/05/45268260/amc-q1-earnings-highlights-double-beat-ceo-highlights-2025-2026-slate-as-box-office-doubles-in-april">AMC Q1 Earnings Highlights: Double Beat, CEO Highlights 2025, 2026 Slate As Box Office Doubles In April</a>
This move builds on AMC's popular Discount Tuesdays and aims to boost midweek attendance. While premium format surcharges and online fees still apply, the base ticket price for formats like IMAX and Dolby Cinema will also receive the 50% discount. 
AMC Chairman and CEO Adam Aron noted the promotion was made possible by a strong box office recovery this spring, with April and May seeing notable success. He added that the initiative could become a long-term strategy if successful. The company hopes Wednesdays will mirror the strong turnout already seen on Tuesdays.
Read Also: <a href="https://www.benzinga.com/25/05/45276888/amc-ceo-says-q1-was-the-worst-domestic-box-office-since-covid-19but-expects-a-rebound-in-2025-with-barn-burners-coming-all-year">AMC CEO Adam Aron Calls Q1 The Worst Domestic Box Office Since COVID-19, But Remains Hopeful For A 2025 Rebound With &#8216;Barn Burners&#8217; Coming All Year</a>
<h2 class="wp-block-heading">How To Buy AMC Stock</h2>
By now you're likely curious about how to participate in the market for AMC Entertainment &#8211; be it to purchase shares, or even attempt to bet against the company.
Buying shares is typically done through a brokerage account. You can find a list of <a href="https://www.benzinga.com/money/best-stock-trading-platforms">possible trading platforms here.</a> Many will allow you to buy &#8220;fractional shares,&#8221; which allows you to own portions of stock without buying an entire share.
In the case of AMC Entertainment, which is trading at $2.81 as of publishing time, $100 would buy you 35.59 shares of stock.
If you're looking to bet against a company, the process is more complex. You'll need access to an options trading platform, or a broker who will allow you to &#8220;go short&#8221; a share of stock by lending you the shares to sell. The process of shorting a <a href="https://www.benzinga.com/money/how-to-short-a-stock">stock can be found at this resource.</a> Otherwise, if your broker allows you to trade options, you can either buy a put option, or sell a call option at a strike price above where shares are currently trading &#8211; either way it allows you to profit off of the share price decline.
According to data from&nbsp;<a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>, AMC has a 52-week high of $11.88 and a 52-week low of $2.45.

AMC Stock Rises As Theater Chain Launches 50% Off Wednesdays

Keefe, Bruyette &amp; Woods analyst Sanjay Sakhrani upgrades Payoneer Global (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PAYO#NASDAQ">PAYO</a>) from Market Perform to Outperform and raises the price target from $7 to $9.

Upgrades

PAYO

Keefe, Bruyette & Woods Upgrades Payoneer Global to Outperform, Raises Price Target to $9

Press Releases

Dogwood Therapeutics Announces Third Quarter 2024 Financial Results

Health Care

Dogwood Therapeutics, Inc. Announces Low Dose IMC-2 Treatment Reduces Long-COVID Related Fatigue and Sleep Disturbance in an Investigator-Initiated Study

Dogwood Therapeutics Announces Patient Dosing in Phase 2b Trial Evaluating Halneuron® in Patients with Chemotherapy Induced Neuropathy (CINP) to Commence First Quarter of 2025

Comments

Dogwood Therapeutics

ニュース

最新ニュース Dogwood Therapeutics (NASDAQ:DWTX) 株価情報

こんな人も見ています

ニュース

パートナーシップ

ベンジンガ・グローバル